We demonstrated that SH42 robustly increases the desmosterol levels in the liver and plasma in both mouse models, accompanied by a reduction in hepatic lipids as shown in E3L.CETP mice, and an improved regulation of circulating monocyte populations as shown in LDLr-KO mice, albeit without affecting atherosclerosis development in either model. This evidence concerns the gene CETP and atherosclerosis.